A drug for the treatment of COVID-19 based on monoclonal antibodies, which is currently being developed by specialists from the Gamaleya State Research Center for Epidemiology and Microbiology, is also effective against the new omicron coronavirus strain. RIA Novosti was told about this by the director of the center, Alexander Gintsburg.
According to him, “the set of monoclonal antibodies has been tested on the omicron and works very well.”
It is assumed that clinical trials of the drug will begin after the New Year holidays.
Recall, on the eve of the “Russia 24” Gunzburg explained that the “omicron” is rapidly spreading and that is why it can cause an increased burden on the health care system. As the academician pointed out, according to preliminary data, there is no need to say that omicron is more dangerous in terms of pathogenicity.
“It’s another matter that it is more contagious, that is, it spreads much better … And this is its danger,” explained the director of the Gamaleya Center. According to him, if the number of patients and hospitalized will grow sharply, health care may “choke”.
We also add that a new strain of coronavirus B.1.1.529, which contains 32 mutations in the S-protein, was first identified in South Africa and Botswana in early November. The infected were found in Hong Kong, Belgium, Israel. At an emergency meeting on November 26, the World Health Organization recognized B.1.1.529 as “of concern” and named it “omicron” after the 15th letter of the Greek alphabet. Omicron has a large number of mutations, it also spreads faster than the delta type. A new strain of coronavirus with increased mobility has been found in more than 85 countries, including Russia.
Source: Rosbalt
Tristin is an accomplished author and journalist, known for his in-depth and engaging writing on sports. He currently works as a writer at 247 News Agency, where he has established himself as a respected voice in the sports industry.
